Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibodies binding ctla-4 and uses thereof

An antibody and monoclonal antibody technology, applied in the direction of antibodies, antibody medical components, medical preparations containing active ingredients, etc., can solve the problem of low quantity

Active Publication Date: 2020-09-11
HARBOUR BIOMED (SHANGHAI) CO LTD
View PDF57 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

CTLA-4 is constitutively expressed on the surface of regulatory T cells, but in relatively low numbers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies binding ctla-4 and uses thereof
  • Antibodies binding ctla-4 and uses thereof
  • Antibodies binding ctla-4 and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0151] Example 1 - Generation of Anti-CTLA-4 Antibodies

[0152] Human CTLA-4-ECD protein (Acro Bio) was used as an immunogen to generate anti-CTLA-4 antibodies. The use of human immunoglobulin transgenic mouse technology to develop and prepare human antibodies was first described in Abgenix (xeno mouse and Medarex (HuMab "mouse"); Lonberg et al., 1994, Nature, 368:856-859; Lonberg and Huszar, 1995, Internal Rev. Immunol., 13:65-93; Harding and Lonberg, 1995, Ann. N.Y. Acad. Sci., 764:536-546).

[0153]HCAb mice were immunized three times every two weeks with human CTLA-4-ECD protein at 20 mg / mouse, and six of them were immunized an additional five times at 44 mg / mouse. With the exception of the first injection, in which Stimune (Prionics) was used as adjuvant, all booster immunizations were performed with Ribi adjuvant (Sigma Adjuvant System S6322-1VL). After immunization, single cell suspensions were isolated from mouse bone marrow, spleen and lymph nodes. Mouse plasma ce...

Embodiment 2

[0165] Example 2-Preparation and purification of anti-CTLA-4 antibody

[0166] Step 1. Preparation of HEK 293F cells overexpressing hCTLA-4

[0167] The nucleotide sequence encoding human CTLA-4 (SEQ ID NO: 196, amino acid sequence encoding SEQ ID NO: 197) was subcloned into pcDNA3.1 vector (Clontech) to obtain a plasmid. HEK293 and CHO-K1 cells (Invitrogen) were transiently transfected with the plasmid using PEI, and the transformants were incubated in DMEM medium containing 0.5 g / mL penicillin / streptomycin and 10% (w / w) fetal bovine serum (FBS). cultured for 2 weeks. Limiting dilutions were performed in 96-well culture plates, and then incubated at 37°C with 5% (v / v) CO 2 Plates were incubated for approximately 2 weeks. Single clones were expanded in 6-well plates, and the expanded clones were screened by flow cytometry using a commercially available anti-hCTLA-4 antibody (R&D Systems). Clones showing higher growth rates and higher fluorescence intensities as measured by...

Embodiment 3

[0175] Example 3 - Characterization of lead candidate antibodies

[0176] 293 cells were stably transfected with the pTT5 plasmid containing the nucleic acid sequence encoding human CTLA-4 (SEQ ID NO: 196) to generate 293F cells stably expressing human CTLA-4 (herein referred to as 293-hCTLA-4 cells). Additional 293 cells were stably transfected with a pIRES plasmid containing the nucleic acid sequence encoding full-length cynomolgus CTLA-4 (SEQ ID NO: 198) to generate 293 cells stably expressing cynomolgus CTLA-4 (referred to herein as 293 -cynoCTLA-4 cells). 293-hCTLA-4 and 293-cynoCTLA-4 cells were cultured and expanded to 90% confluency in T-75 flasks. The medium was aspirated and the cells were washed twice with HBSS (Hanks' Balanced Salt Solution, Invitrogen). Cells were treated with enzyme-free cell dissociation solution (Versene solution, Invitrogen) and collected. Cells were then washed twice with HBSS, cell count determined, and 2x10 6 cells / mL and resuspend the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.

Description

[0001] field of invention [0002] The present invention relates to a monoclonal anti-CTLA-4 antibody, a nucleic acid encoding the antibody, an expression vector and a recombinant cell containing the nucleic acid, and a pharmaceutical composition containing the antibody. Also provided are methods of making the antibodies and methods of using the antibodies to treat diseases including cancer and autoimmune diseases. [0003] Background of the invention [0004] Cancer immunotherapy is the latest breakthrough in cancer treatment, which uses a patient's own immune system to attack tumor cells. Promoting a robust CD8 T cell-dependent cytotoxic response in the tumor microenvironment is important for generating effective antitumor immune responses. However, tumors tend to evade immune surveillance by exploiting T cell suppressive mechanisms. Depletion of tumor-infiltrating lymphocytes (TILs) leads to anergy of cytotoxic T cells and escape of tumor cells (Wherry and Kurachi, 2015, N...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28A61K39/395A61P35/00
CPCC07K16/2818A61K39/3955A61K45/06A61P35/00A61P35/02A61P37/02C07K2317/21C07K2317/24C07K2317/33C07K2317/51C07K2317/52C07K2317/56C07K2317/565C07K2317/70C07K2317/72C07K2317/732C07K2317/76C07K2317/92C07K2317/94A61K2039/505A61K2300/00Y02A50/30C07K16/2878A61P37/00C12N15/63
Inventor 甘馨何云沈宇强赵久乔戎一平F·格罗斯维尔德D·德拉贝克M(R)·范哈佩恩R·扬森
Owner HARBOUR BIOMED (SHANGHAI) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com